clinical trial · NCT05975645
A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·phase1·terminated·n = 29
Advanced Hepatocellular CarcinomaPenpulimab injectionTQB2618 injectionAnlotinib Hydrochloride Capsules
brief summary
This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQB2618 injection combined with penpulimab injection and Anlotinib Hydrochloride Capsules in patients with advanced HCC.
started
Aug 15, 2023
primary completion
Jun 4, 2025
completion
Jun 4, 2025
last updated
Aug 12, 2025
official title
A Phase Ib Clinical Study to Evaluate the Efficacy and Safety of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules as First-line Treatment for Advanced Hepatocellular Carcinoma.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol